Depression and anxiety are highly prevalent among adolescents and adults in Morocco, while access to evidence-based care in primary care centers and schools remains limited. This multicenter pragmatic randomized controlled trial evaluates an integrated mental health program inspired by WHO priorities. The INNOV5 intervention combines: (1) a collaborative care model in primary care; (2) mhGAP-based task-shifting and stepped care; (3) validated digital mental health interventions; (4) virtual reality exposure therapy for selected anxiety- or trauma-related cases; and (5) a school-based mental health promotion component in participating high schools. The primary objective is to compare the change in depressive symptoms (PHQ-9) at 6 months between INNOV5 and enhanced treatment as usual (TAU+). Secondary objectives include effects on anxiety (GAD-7), quality of life (WHOQOL-BREF), suicidal ideation and behavior (C-SSRS), functioning, school attendance, and feasibility and acceptability of the program.

Inclusion Criteria:

• Adolescents (12-17 years) and adults (≥18 years) attending participating primary care centres or high schools in Morocco.
• Clinically significant depressive and/or anxiety symptoms identified by screening (PHQ-9 and/or GAD-7) according to study thresholds.
• Able to understand study procedures and provide informed consent (or parental consent and adolescent assent for minors).
• Planning to remain in the study area for at least 12 months.

Exclusion Criteria:

• Acute psychiatric emergency requiring immediate specialised care (e.g. psychosis, high-risk suicidal crisis, severe substance use disorder).
• Cognitive impairment or severe medical condition preventing participation in the intervention or assessments.
• Current participation in another interventional mental health trial.
• Any other situation judged by the investigator to make participation unsafe or inappropriate.

De-identified individual participant data (IPD) underlying the primary and secondary outcome analyses will be made available to qualified researchers upon reasonable request, after completion of the trial and publication of the main results. Data sharing will comply with Moroccan data protection law (Loi 09-08), CNDP authorization and institutional policies. A data sharing agreement will be required.

From 12 months after publication of the primary trial results and for up to 5 years thereafter.

Researchers must submit a brief research proposal and analysis plan to the Swiss Medical Academy data access committee (contact@swissmedicalacademy.ma

). Requests will be reviewed for scientific merit, ethical approval and compliance with data protection regulations. Upon approval and signature of a data sharing agreement, de-identified IPD will be transferred via a secure data sharing platform.